Peter Saway, MD
Rheumatology · Mountain Brk, ALNPI 1417932849
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $118,367 of the $166,265 with a category attached, or 71.2%. Amgen accounts for 75.0% of it on its own, with 31 other manufacturers making up the rest. Reporting peaked in 2019 at $86,342 and has fallen 84.3% since, to $13,564 in 2025. Among rheumatology clinicians in AL with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 1,569 payments — averaging $105.97 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Amgen$125K
- Radius Health, Inc.$20K
- AbbVie$5K
- UCB, Inc.$2K
- Novartis$2K
- GSK$2K
- plus $11K from 26 others
What the payments were for
- Speaking & faculty fees$118,36771%
- Travel & lodging$16,17210%
- Food & beverage$31,21119%
- Education$5150%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Amgen(2 entities) | 408 | $124,758 |
| Radius Health, Inc. | 54 | $19,609 |
| AbbVie | 272 | $5,499 |
| UCB, Inc. | 122 | $2,246 |
| Novartis | 99 | $1,995 |
| GSK | 77 | $1,541 |
| Johnson & Johnson | 73 | $1,432 |
| E.r. Squibb & Sons, L.L.C. | 85 | $1,410 |
| Pfizer | 102 | $1,357 |
| AstraZeneca(2 entities) | 38 | $1,108 |
| Mallinckrodt Hospital Products Inc. | 36 | $835 |
| Lilly USA, LLC | 36 | $713 |
| Aurinia Pharma U.S., Inc. | 22 | $647 |
| ANI Pharmaceuticals, Inc. | 17 | $472 |
| Boehringer Ingelheim | 14 | $419 |
| Genentech USA, Inc. | 18 | $301 |
| Medexus Pharma, Inc. | 10 | $286 |
| Sanofi | 5 | $271 |
| Pacira Therapeutics, Inc. | 15 | $252 |
| Sobi, Inc | 12 | $210 |
| Organon | 14 | $200 |
| Fresenius Kabi USA, LLC | 8 | $148 |
| Bristol Myers Squibb | 10 | $140 |
| Mallinckrodt Enterprises LLC | 6 | $110 |
| Ultragenyx Pharmaceutical Inc. | 4 | $85 |
| Sandoz | 4 | $80 |
| Pacira Pharmaceuticals Incorporated | 3 | $60 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $24 |
| Medtronic | 1 | $18 |
| Genentech, Inc. | 1 | $14 |
| Ferring Pharmaceuticals Inc. | 1 | $13 |
| Collegium Pharmaceutical, Inc. | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$166,265 in reported general payments places this provider in the 90th percentile of 90 rheumatology providers in Alabama.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Humira(Cf) PenAdalimumab | 31 | $297,159 |
| Humira(Cf)Adalimumab | 39 | $269,860 |
| EnbrelEtanercept | 31 | $233,224 |
| RinvoqUpadacitinib | 35 | $232,790 |
| Enbrel SureclickEtanercept | 29 | $211,789 |
| LupkynisVoclosporin | 11 | $109,908 |
| OtezlaApremilast | 19 | $87,047 |
| RayosPrednisone | 12 | $31,282 |
| Hydroxychloroquine Sulfate | 614 | $30,156 |
| NucyntaTapentadol Hcl | 11 | $13,103 |
| Pregabalin | 154 | $8,759 |
| OxycontinOxycodone Hcl | 12 | $6,734 |
| Celecoxib | 135 | $6,099 |
| Tramadol Hcl ErTramadol Hcl | 45 | $5,750 |
| Cevimeline Hcl | 28 | $5,374 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieHumira(Cf), Rinvoq | $5,499 | $502,65074 claims |
| AmgenEnbrel, Otezla, Rayos | $124,758 | $351,55362 claims |
| Aurinia Pharma U.S., Inc.Lupkynis | $647 | $109,90811 claims |
| Collegium Pharmaceutical, Inc.Nucynta | $13 | $13,10311 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 90 rheumatology providers in Alabama.
Other rheumatology in Mountain Brk
- Anthony TurkiewiczMountain Brk$2.2M
- Maura KennedyMountain Brk$18K
- Laura ParksMountain Brk$16K
- Joel AbbottMountain Brk$14K
- William PaulMountain Brk$7K
- Jeffrey CurtisBirmingham$612K
- David McLainBirmingham$588K
- Ray McLaughinTuscaloosa$332K
- Elizabeth PerkinsHoover$264K
- Kenneth SaagBirmingham$143K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.